Research programme: adeno-associated virus based gene therapies - AGTC/Synpromics

Drug Profile

Research programme: adeno-associated virus based gene therapies - AGTC/Synpromics

Alternative Names: AAV-based gene therapies

Latest Information Update: 11 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Applied Genetic Technologies Corporation
  • Class
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 10 Nov 2017 Applied Genetic Technologies Corporation receives patent allowance for method of adeno-associated virus based gene therapies manufacturing in USA, before November 2017
  • 09 Dec 2015 AGTC and Synpromics enter into a research collaboration for the development of synthetic promotors as gene therapy candidate
  • 09 Dec 2015 Early research in Undefined indication in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top